, 24.4.

2015

&

1.

2.

,
.

3.

, : ,

.

10.0

HbA1c (%)

~ 20% 40%
A1c >9.5%

9.5

NHANES/BRFSS; Harmel, et al.; NCQA 2000

9.0
~ 40% 50%
A1c >8%

8.5

NHANES/BRFSS; Harmel, et al.

8.0
~ 30% 2 7.5

A1c <8%
7.0
Harmel et al.
6.5
6.0

<7
< 6.5
6

ADA

AACE/ACE

5.5
ADA. Diabetes Care 2003; 26(Suppl 1): S33-S50
ACE. Consensus Conference on Guidelines for Glycemic Control. Endocrine Practice 2002
NCQA. Health Plan Employer Data and Information Set (HEDIS) 2000
NCQA. State of Managed Care Quality 2000

P<0.001

P<0.001

P<0.001

7%
140mmHg
150mg/dl

100mg/dl

40/50mg/dl

LIATIS ET AL ,2013

Steno 2 study:

IGT

(Uncontrolle
d)

(mg/dl)

126

100

()

20

10

10

20

30

Adapted from Bergenstal RM, et al. Diabetes mellitus, carbohydrate metabolism and lipid disorders. In
Endocrinology. 4th ed. 2001.

Diabetes Care 2015;38(Suppl. 1):S41S48


...
,

.

, ,
.

DiabetesCare,Diabetologia.19April2012

ADA-EASD:
2

///

-
-
-
-
-
-
DiabetesCare,Diabetologia.19April2012

 ,

,

.

H
HbA1c>8% 2


+
2-3
>7%

+
+ TZD
MET + SU
+ GLIN
MET + CAR
+ DPP-4
+ GLP-1

. ..

MICHAEL N. COOK DIABETES CARE, VOLUME 28, NUMBER

5, MAY 2005


HbA1c
10
27b
8,8

HbA1c, %

35b
9,1

(n=513 )

(n=3.394 )

7,7
7,1
ADA

IDF

6
0

HbA1c

HbA1c
c

ADA= , IDF= .
, 19942002, b .
c .
Brown JB et al. Diabetes Care. 2004;27(7):15351540; American Diabetes Association. Diabetes Care. 2010;33(suppl 1):S11S61;
International Diabetes Federation. www.idf.org/webdata/docs/Guideline_PMG.pdf. Accessed September 2, 2010.
a

. Aloumanis et al Primary care Diabetes 2013

Conventional*
Glibenclamide
Metformin
Insulin

HbA1c (%)

8.5
8
7.5
7

Recommended treatment
target <7.0%

6.5
6

6.2% upper limit of normal range

0

Years from randomisation

*Diet initially then sulphonylureas, insulin and/or metformin if FPG>15 mmol/L
ADA clinical practice recommendations. UKPDS 34, n=1704

UKPDS 34. Lancet 1998:352:85465; Kahn et al. NEJM 2006;355(23):242743

10

Agency for Healthcare Research &

Quality:
&

2
A 1%

1c

.
A1c,

.

(, ,
) .
3.
2011 by American College of Physicians

BennettWL,etal.AnnInternMed2011;154:602

ADA-EASD:
2

.
, & :
2
, = 1 .
, .
1-2 /
.
,
/
.

.

( , &

DiabetesCare,Diabetologia.19April2012

 vs

 vs

:
, , ,
,
Diet
, ,
,
,

Eating
pattern
Eating plan

,

.

1
Leiter et al.

15%
2


2
(58%)
Leiter et al.
2

1. Data on file. Market Research Novo Nordisk Nov. 2010 2. Leiter, et al. Can J Diabetes 2005;29(3):186-92

:
,
< 60 ml/min per 1.73 m(2),
,
,
.
HbA1c
.
DavisClin Endocrinol Metab. 2010


2


.

.
2
,
/ .

15 15

15 grams
3 4 tablets
4,5 dL
1

15 -
<80 mg/dl , 15 grams

> 1

Glucagon

kits

!!!!

Range of weight change (kg) in response

to diabetes medications1,2
Sulphonylureas
Glinides
Thiazolidinediones
Insulin
DPP-4 inhibitor (sitagliptin)
Metformin
GLP-1 receptor agonist (exenatide)
Dapagliflozin
6

10

Range of weight change (kg)

1. Mitri J, Hamdy O. Expert Opin Drug Saf 2009;8:57384; 2. Clar C, et al. BMJ 2012;2:e00107.
1055HQ13NP05636-01

Median 95% confidence interval

Biphasic
prandial

Prandial
basal

Basal
prandial

 During the Diabetes Control and Complications Trial, insulin-treated patients

with severe hypoglycaemia had a significantly (P<0.05) greater increase in
weight than those without severe hypoglycaemia

Patients with severe

hypoglycaemia

+6.8 kg

Patients without severe

hypoglycaemia

+4.6 kg

Weight gain (kg)

A potential explanation for this is defensive snacking an increase in

a patients carbohydrate intake following hypoglycaemia due to their fear of
further events
Russell-Jones D, Khan R. Diabetes Obes Metab 2007;9:799812.
1055HQ13NP05636-01

.


\

.

(:
, :
UKPDS,ADVANCE)

\ \

\ \

(,
, )

(Candida )

()

(
,
() \ () \

( ,
)

\
(, ,
)

LDL-

( ,
)
\
.

.\
.\
.\
.

.

GL-1
TZD
SGLT-2


, ( 500 )


1.
2. 2
3.

Diabetes Care 2010; 33: 240 245

(

)

.
.

,
( ,
)
.
.

(
2).

, , (GLP-1 )

(GLP-1 )

(;)

(;)

1.

2.

3.

4.